» Articles » PMID: 23505965

Boosting Immunity to Small Tumor-associated Carbohydrates with Bacteriophage Qβ Capsids

Overview
Journal ACS Chem Biol
Specialties Biochemistry
Biology
Date 2013 Mar 20
PMID 23505965
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

The development of an effective immunotherapy is an attractive strategy toward cancer treatment. Tumor associated carbohydrate antigens (TACAs) are overexpressed on a variety of cancer cell surfaces, which present tempting targets for anticancer vaccine development. However, such carbohydrates are often poorly immunogenic. To overcome this challenge, we show here that the display of a very weak TACA, the monomeric Tn antigen, on bacteriophage Qβ virus-like particles elicits powerful humoral responses to the carbohydrate. The effects of adjuvants, antigen display pattern, and vaccine dose on the strength and subclasses of antibody responses were established. The local density of antigen rather than the total amount of antigen administered was found to be crucial for induction of high Tn-specific IgG titers. The ability to display antigens in an organized and high density manner is a key advantage of virus-like particles such as Qβ as vaccine carriers. Glycan microarray analysis showed that the antibodies generated were highly selective toward Tn antigens. Furthermore, Qβ elicited much higher levels of IgG antibodies than other types of virus-like particles, and the IgG antibodies produced reacted strongly with the native Tn antigens on human leukemia cells. Thus, Qβ presents a highly attractive platform for the development of carbohydrate-based anticancer vaccines.

Citing Articles

Nanoparticles as Delivery Systems for Antigenic Saccharides: From Conjugation Chemistry to Vaccine Design.

Archambault M, Tshibwabwa L, Cote-Cyr M, Moffet S, Shiao T, Bourgault S Vaccines (Basel). 2024; 12(11).

PMID: 39591192 PMC: 11598982. DOI: 10.3390/vaccines12111290.


Inducing Long Lasting B Cell and T Cell Immunity Against Multiple Variants of SARS-CoV-2 Through Mutant Bacteriophage Qβ-Receptor Binding Domain Conjugate.

Tan Z, Yang C, Lin P, Ramadan S, Yang W, Rashidi Z Adv Healthc Mater. 2024; 13(20):e2302755.

PMID: 38733291 PMC: 11305917. DOI: 10.1002/adhm.202302755.


A comprehensive synthetic library of poly-N-acetyl glucosamines enabled vaccine against lethal challenges of Staphylococcus aureus.

Tan Z, Yang W, OBrien N, Pan X, Ramadan S, Marsh T Nat Commun. 2024; 15(1):3420.

PMID: 38658531 PMC: 11043332. DOI: 10.1038/s41467-024-47457-4.


Development of NHAcGD2/NHAcGD3 conjugates of bacteriophage MX1 virus-like particles as anticancer vaccines.

Zhao Q, Huang X, Wu X RSC Adv. 2024; 14(9):6246-6252.

PMID: 38375005 PMC: 10875654. DOI: 10.1039/d3ra08923a.


Serum antibody screening using glycan arrays.

Marglous S, Brown C, Padler-Karavani V, Cummings R, Gildersleeve J Chem Soc Rev. 2024; 53(5):2603-2642.

PMID: 38305761 PMC: 7616341. DOI: 10.1039/d3cs00693j.


References
1.
Ni J, Song H, Wang Y, Stamatos N, Wang L . Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates. Bioconjug Chem. 2006; 17(2):493-500. DOI: 10.1021/bc0502816. View

2.
Lau J, Baksh M, Fiedler J, Brown S, Kussrow A, Bornhop D . Evolution and protein packaging of small-molecule RNA aptamers. ACS Nano. 2011; 5(10):7722-9. PMC: 3209476. DOI: 10.1021/nn2006927. View

3.
De Silva R, Wang Q, Chidley T, Appulage D, Andreana P . Immunological response from an entirely carbohydrate antigen: design of synthetic vaccines based on Tn-PS A1 conjugates. J Am Chem Soc. 2009; 131(28):9622-3. DOI: 10.1021/ja902607a. View

4.
Snapper C, McIntyre T, Mandler R, Pecanha L, Finkelman F, Lees A . Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J Exp Med. 1992; 175(5):1367-71. PMC: 2119217. DOI: 10.1084/jem.175.5.1367. View

5.
Chen W, Gu L, Zhang W, Motari E, Cai L, Styslinger T . L-rhamnose antigen: a promising alternative to α-gal for cancer immunotherapies. ACS Chem Biol. 2010; 6(2):185-91. DOI: 10.1021/cb100318z. View